(NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q3, starting ...

Quest Diagnostics DGX is well-poised to grow in the coming quarters, supported by its value-creating, strategic acquisitions. The company’s Advanced Diagnostics offerings deliver and scale innovative ...

Hims & Hers—the virtual care platform with about 2.5 million subscribers—will now offer laboratory testing through Quest Diagnostics. Customers will have access to more than 120 biomarker tests across ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

During the year, the industry saw continued consolidation, the end of a key advisory body, the rise in DTC testing and advanced diagnostics, and another stab at PAMA reform.

Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.

Quest Diagnostics handles the blood and other biological specimens of one in three Americans every year, and in Temple ...

A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use ...

Truvian Health’s device, TruVerus, processes routine blood tests in less than 30 minutes outside traditional labs and has earned FDA clearance.

The study suggests the tests could save lives by catching cancer at earlier stages, when it's more easily treated. It predicted that, over a decade of use, MCEDs could reduce stage IV cancer diagnoses ...

Laboratories dealing with both clinical and molecular diagnostics need an informatics solution that enables them to efficiently handle end-to-end processes, ranging from receiving test requests to ...